MODEL BIOCLUSTERS Including Those Not Chosen

Annex 2. The list of MODEL BIOCLUSTERS including those not chosen

The tables below provide the information on the pool of all preselected bioclusters existing in Europe, USA, Canada, and Asia. Clusters in Europe

Upper Austrian Food Cluster AUSTRIA (Lebensmittel-cluster, Linz, Province of Upper Austria)

1. General Information o Cluster development stage o - Early development/Growing o - Established in 2000 as the Upper Austrian Food Cluster (LC OÖ). o - Evolution of the LC OÖ network has been extremely dynamic since the formation of the cluster. 2. Scientific Base o -N.d. 3. Industrial Base o - N.d. 4. Financial Base o Government Funds: names of o - Measures within the framework of the Upper Austrian Food Cluster are funds, investment conditions, financed by the Province of Upper Austria, the Upper Austrian Chamber of volume of capital Commerce and contributions from network partners. 5. Support Base o - N.d. 6. Cooperation and aggregation o Cooperation other clusters in o - Use of synergy to enhance innovatory strength improves regional and supra- different regions and/or countries regional competitiveness. - Increasing competitiveness and innovatory strength through co-operation is highly emphasized. o Cooperation or aggregation via o - Close co-operation within the LC OÖ network between the farming industry other means and commerce. Over 1.000 farmers are involved in LC OÖ projects. 7. Additional information o – N.d. 8. Sources o http://www.lebensmittelcluster.at/startseite/lebensmittel_cluster/english_descri ption.html

Agrobiopole Wallon BELGIUM (Gembloux,Waloonia Region)

1. General Information o Cluster development stage o -Amount of staff: 22 o Cluster objectives o - Main objectives are to federate experts in diverse sectors in bioraffinage, reinforce its activities and to position its experts on a European scene. o - Assists organizations that develop their activities in terms of bioraffinage. o - Pole of excellence in the fields of agronomy and biotechnologies in general,

1 Agrobiopole Wallon BELGIUM (Gembloux,Waloonia Region)

with the mission to serve the development of the region Walloonia o Number of publicly traded o - Affiliated companies include Pharma manufacturing, Wetlands engineering, companies Agrostar and Immolabo. - Scientific institutions, private organizations, associations and public institutions. 2. Scientific Base o – N.d. 3. Industrial Base o – N.d. 4. Financial Base o Government Funds: names of funds, o - Dependant from governmental sponsors such as the Walloon Region, State of investment conditions, volume of Belgium or the European Union- capital 5. Support Base o – N.d. 6. Cooperation and aggregation o – N.d. 7. Additional information o – N.d. 8. Sources o http://www.agrobiopole.be/pdf/Plaquette%20FRsept09.pdf

Ghent Bio-Energy Valley BELGIUM (Ghent, Flanders Region)

1. General Information o Cluster development stage o -Early development/ growing o -Founded in 2005. o - Leading initiative in development biobased economy. o Cluster objectives o - Promotes the development of the biobased economy through collaborative programs, joint initiatives and synergy creation between the partners in the fields of R&D, structural measures and policy, logistics and communication towards the general public o - Ultimate aim of Ghent Bio-energy valley is to promote the development of the so-called knowledge-based bio-economy o Number of publicly traded o - Major industrial partners include Electrabel – GDF-Suez, Cargill and companies Capricorn o - Electrabel is the key energy player in Belgium. 2. Scientific Base o Number of universities: names of o - University of Ghent main player in biotechnology. The university is the major ones, research focus and largest one in the Dutch speaking area with approximately 60,000 students and number of students 2600 international students. o -Flemish institute of biotechnology (Incorporated in the University of Ghent), one of the world’s leading institutes in biotechnology. o - Great biotechnologic expertise in Flanders. o Number of research institutes: o - About 11 Research groups. names of major ones, research focus areas and number of employees

2 Ghent Bio-Energy Valley BELGIUM (Ghent, Flanders Region)

3. Industrial Base o - N.d. 4. Financial Base o - N.d. o Government Funds: names of funds, o - Recently, the EU gave a € 6 million subsidy for Bio Base Europe investment conditions, volume of capital 5. Support Base o Legal regime: specialized legal o - Belgium is one of the last countries in the EU where a legal framework in structures incl. tax cuts regards to adding bio fuel is still absent. The issue is currently being addressed.

6. Cooperation and aggregation o Cooperation other clusters in o - December 2008: Europe, Flanders and The Netherlands have joined forces different regions and/or countries within the framework of an Interreg IV project and allocated € 21 million to Bio Base Europe. o - Bio Base Europe is the result of a partnership between Ghent Bio-Energy Valley and Biopark Terneuzen and their respective stakeholders. o -Largest Interregion project ever granted to the Dutch-Flemish border-region o Cooperation or aggregation via other o - Joint initiative of Ghent University, the Port of Ghent, the Development means Agency of East-Flanders and a number of industrial companies in the Greater Ghent area. 7. Additional information o – N.d. 8. Sources o http://www.gbev.org/web/en.php o http://www.gbev.org/pdf/GBEV%20workshop%2018%20mei%2009.pdf o http://www.vilt.be/Wout_Boerjan__VIB/Gent_blijft_wereldtop_in_groene_bio technologie

Aarhus Cluster DENMARK

1. General Information o Cluster development stage o - Early development: Cluster of Aarhus is still in its embryonic phase. o Number of publicly traded o - Cluster currently encompasses 22 DBFs, of which the large majority has less companies than 5 employees. - 9 out of 22 DBFs operate in drug discovery processes, 4 in specializing diagnostic tools and the others mainly provide support services. o Estimated ratio biomedical versus o - Large majority of biotech companies in the cluster were founded between non-biomedical companies: XY 1998 and 2001 in correspondence with the global economic growth period 2. Scientific Base o Number of universities: names of o - Aarhus region is a major education and research center, providing a major ones, research focus and favourable background for the cluster birth. number of students 3. Industrial Base o Number of large enterprises in o - Includes promising high growth companies, 75% of which are located in the

3 Aarhus Cluster DENMARK

biotech: names of major ones, science park product focus areas, number of employees o Existing success stories in biotech: o - 33% of the recently founded DBFs are already profitable but overall turnover well-known products/ business remains low cases/ companies 4. Financial Base o Government Funds: names of funds, o - Danish government has invested massively in the biotech industry. investment conditions, volume of capital 5. Support Base o Cluster promotion agencies (incl. o Availability of science parks (i.e. Aarhus Science Park and the Biomedical Science parks, incubators): name, Science Park) function 6. Cooperation and aggregation o - N.d. 7. Additional information o - N.d. 8. Sources o http://books.google.lu/books?id=T_MYEg9phXEC&pg=PA92&lpg=PA92&d q=aarhus+cluster&source=bl&ots=malKS7WInB&sig=4zItCv95AwggfXRsjq AHCVqDLWI&hl=de&ei=P2HlSqTIKs2K4QaR8NmLDQ&sa=X&oi=book_r esult&ct=result&resnum=1&ved=0CAcQ6AEwAA#v=onepage&q=aarhus%2 0cluster&f=false

Medicon Valley DENMARK –SWEDEN (Greater Copenhagen and Skåne Region)

1. General Information o Cluster development stage o – Mature o - One of Europe's strongest life science clusters o Cluster typology o - Hybrid o - Unique interplay between hospitals, universities, public research institutions, industry and investors.

o Number of publicly traded o - Cluster with over 100 biotech companies, more than 200 medtech companies companies and more than 50 relevant service providers. 2. Scientific Base o Number of universities: names of o - Comprises a dense cluster of universities, hospitals and companies within life major ones, research focus and science, many of which are R&D based. number of students 3. Industrial Base o Number of large enterprises in o - Companies such as Novo Nordisk, H. Lundbeck, AstraZeneca and LEO biotech: names of major ones, Pharma, have significantly contributed to the development of the region by product focus areas, number of strengthening abilities within applied research, attracting suppliers and

4 Medicon Valley DENMARK –SWEDEN (Greater Copenhagen and Skåne Region)

employees producing spin-offs 4. Financial Base o Government Funds: names of funds, o - Medicon valley relies on both private and public R&D spending and both the investment conditions, volume of Danish and Swedish governments are dedicated to increasing R&D spending capital over the coming years 5. Support Base o - N.d. 6. Cooperation and aggregation o Cooperation other clusters in o - Interregion project. different regions and/or countries o - Public authorities and life science industry in Copenhagen and Southern Sweden agreed to market the region internationally and aim to become the most attractive bioregion in Europe. 7. Additional information o - N.d. 8. Sources o http://www.mediconvalley.com/ o www.mva.org

Agropolis International (Montpelier) FRANCE

1. General Information o Cluster development stage o - Maturing: Founded in 1986. o Number of publicly traded o - 1 consultation group, 25 associated members and 4 local authorities. companies 2. Scientific Base o Number of research institutes: o - 8 Research establishments names of major ones, research focus areas and number of employees 3. Industrial Base o - N.d. 4. Financial Base o - N.d. 5. Support Base o - N.d. 6. Cooperation and aggregation o Cooperation or aggregation via other o - Support of the ministeries for research, agriculture and cooperation means 7. Additional information o - N.d. 8. Sources o http://www.agropolis.org/

5 Biovalley cluster FRANCE, GERMANY, SWITZERLAND

1. General Information o Cluster development stage o - One of the largest biotech-regions in Europe o - Total employment within cluster: >250,000 employees (2005) o - Period of strong growth in 1997-2000 o - spin-off activities from Novartis supported by public actors; o Cluster typology o - No cluster formation took place before public intervention 2. Scientific Base o Number of universities: names of o - 100,000 students major ones, research focus and o - 12 Universities and academic institutes (Life Sciences, Biotech, Chemistry number of students and Neuroscience) o - 50,000 employed in the sector o - >30 qualified technology platforms for scientific services: Screening, ADME, Spectroscopy, NMR, Phenotyping, Clinical research, etc. o Number of research institutes: o - 40 scientific institutions names of major ones, research focus areas and number of employees o Famous Scientists working on o - High level of scientific research indicated by 5 Nobel Prizes in the last few campus: e.g. Nobel Prize winners decades

o O Establishment of the legal structure of BioValley (www ther information 3. Industrial Base o Number of large enterprises in o - 600 companies, including 40% of the biggest pharmaceuticals companies in biotech: names of major ones, the world including Abbot, Dow Chemical, Clariant, DuPont, Eli Lilly, product focus areas, number of Johnson & Johnson, Novartis, Pfizer, Roche, Sanofi-Aventis, Syngenta, etc. employees 4. Financial Base o Government Funds: names of funds, o - 1997: BioValley programme obtained €2,2 mln through the Interreg II investment conditions, volume of Program of EU capital 5. Support Base o Cluster promotion agencies (incl. o - 11 Life Sciences Parks Science parks, incubators): name, o - 40 scientific institutions function o Public acceptance of biotech o - Coordination by multiple public actors (including central and local activities: governmental support, governments); etc. o Legal regime: specialized legal o 1998:.biovalley.com): 3 national associations and a central tri-national structures incl. tax cuts association. 6. Cooperation and aggregation o Cooperation other clusters in o Cluster is located in 3 countries: France, Germany and Switzerland : Upper different regions and/or countries Rhine Valley: Alsace, South Baden and North West Switzerland o -3city axis: Strasbourg, Freiburg and Basel o 2002-2007: Interreg III European Program for BioValley with a budget of €2.8 mln: "BioValley: from network to tri-national biotech cluster". o Transnational integration processes intended to form a region of high

6 Biovalley cluster FRANCE, GERMANY, SWITZERLAND

competitiveness. 7. Additional information o - N.d. 8. Sources o – www.biovalley.com

Bretagne (Rennes) FRANCE

1. General Information o Cluster typology o - Policy-driven 2. Scientific Base o - N.d. 3. Industrial Base o - N.d. 4. Financial Base o Government Funds: names of funds, o - Financing dependant on state, Oseo/ANVAR and the local council. investment conditions, volume of capital 5. Support Base o Public acceptance of biotech o - Working closely together with governmental organizations. activities: governmental support, etc. 6. Cooperation and aggregation o - N.d. 7. Additional information o - N.d. 8. Sources o http://www.pole-valorial.fr/valorial/index.php

Champagne-Ardenne and Picardie FRANCE (Troyes)

1. General Information o Cluster development stage o - Growing: aims to become the European leader for non-food agricultural resources by the year 2015. o Cluster objectives o - Aims to develop an economic intelligence tool specialized in opportunities for fossil fuel substitution and to adapt and mobilize the plant resources necessary for industrial application 2. Scientific Base o Number of universities: names of o - The region is home to over 35,000 college and university students specialized major ones, research focus and in often unique disciplines. number of students 3. Industrial Base o Number of large enterprises in o - Total partners: 95. The majority are companies including L’Oréal, Electricité

7 Champagne-Ardenne and Picardie FRANCE (Troyes)

biotech: names of major ones, de France, Gaz de France-Suez, Crédit Agricole, Airbus and Solvay. product focus areas, number of employees 4. Financial Base o - N.d. 5. Support Base o Area Attractiveness: unique context o - The Champagne-Ardenne and Picardy regions are 2 French regions of the area/region recognized for their agricultural potential. o - Champagne-Ardenne enjoys the highest percentage of jobs resulting from foreign direct investments due to the regions solid technology base, strategic location and infrastructure.

6. Cooperation and aggregation o Cooperation other clusters in o Cluster wants to intensify the partnerships between the 2 member regions and different regions and/or countries aims to extent its alliance with other national or international participants o - Aim to develop its expertise at an international level in bio-fuels, energy and food-related products and the recovery of vegetable matter 7. Additional information o - N.d. 8. Sources o http://documents.eu-japan.eu/seminars/japan/fdi/report_champagne_oct08.pdf o http://www.invest-in-france.org/international/en/iar-cluster.html

Grenoble Alpes Bio Network FRANCE (Grenoble Area)

1. General Information o Cluster development stage o – Growing o - Part of ADEBAG: Association for the Development of Bioindustry in the Grenoble Area, created in 2000. o Cluster typology o - Non profit organization federating public and private actors 2. Scientific Base o Number of universities: names of o - 3 universities major ones, research focus and o - Joseph Fourier University (UJF), Pierre Mendès France University (UPMF) and Grenoble Institute of Technology (INPG). number of students

o Number of research institutes: o - 5 research centres names of major ones, research focus o - Grenoble University Hospital (CHUG), CEA, INRIA Rhône-Alpes, CNRS CERMAV, CEA IBS (Structural Biology Institute). areas and number of employees 3. Industrial Base o Number of large enterprises in o - 24 SMEs and start-up companies biotech: names of major ones, o - 3 large companies and public local authorities - Leading companies include BD France, Bio Mérieux and Roche Diagnostics product focus areas, number of o employees 4. Financial Base o - N.d. 5. Support Base o - N.d. 6. Cooperation and aggregation o Cooperation other clusters in o - BioAlpine Cluster: Agreement in 2006 by Western Switzerland,

8 Grenoble Alpes Bio Network FRANCE (Grenoble Area)

different regions and/or countries Grenoble/Rhône-Alpes (France) and Turin/Piedmont (Italy) – all unique for the sectors of bio and medical technologies. Members are open to the idea of other European partnerships. o - Aim to create a cross-border Alpine zone of European if not international scope. 7. Additional information o - N.d. 8. Sources o http://www.adebag.org/uk/adebag.html

Paris/Ile de France FRANCE (Greater Paris Region)

1. General Information o Cluster development stage o - Medicen Paris Region Cluster o -Growing: Certified in 2005. o - Aim is to become one of the world leaders in the biomedical innovation field by 2012 o Cluster typology o - Spontaneous o - Cluster has over 160 members with the majority consisting of companies. The remaining are organisations for R&D and local councils o Cluster objectives o - To specialize in High Technology for Health and New Therapies 2. Scientific Base o Number of universities: names of o - 9 universities and 20 grandes écoles major ones, research focus and o - Ecole Centrale de Paris, Ecole Polytechnique, Ecole Normale Supérieure de number of students Cachan, Université de Cergy-Pontoise, Université de Versailles et Saint- Quentin-en-Yvelines, Université de Paris XII Val-de-Marne o Number of research institutes: o - over 300 public and private research laboratories. names of major ones, research focus o - Institut Curie, Institut Pasteur, Centre National de la Recherche Scientifique areas and number of employees (CNRS) o - Ile-de-France is home to the world leaders in the pharmaceutical industry and has about 50% of French biotechnology 3. Industrial Base o Number of large enterprises in o - Members are Small- and medium-sized enterprises, Large companies, biotech: names of major ones, Research and Local authorities product focus areas, number of o - 115 companies; 103 are small- and medium-sized; 12 are large employees o - large companies are: Sanofi-Aventis, Servier, Ipsen, Guerbet, GE HealthCare, GlaxoSmithKline, Phillips Medical System, Siemens Medical Solutions, Bio-Rad France, CIS Bio international, Innothera Services, LFB

4. Financial Base o Government Funds: names of funds, o - 43 million euros have been financed through various public subsidies: The investment conditions, volume of Single Interministerial Fund (Fonds Unique Interministériel or FUI) and the capital subsidies of local Ile-de-France councils; The National Research Agency (Agence Nationale de la Recherche); namely the financing partners are:

9 Paris/Ile de France FRANCE (Greater Paris Region)

o ANR (Agence national de recherché) o Agence régional de développement – ARD - Paris Ile de France o Conseil Général 91 o Conseil Général des Hauts-de-Seines (CG 92) o Conseil Général Seine-Saint-Denis (CG 93) o Conseil Général de Val-de-Marne (CG 94) o Conseil Général du Val d’Oise (CG95) o Conseil Régional Ile de France o Direction Régional de l’Industrie, de la Recherche et de l’Environnement o Ministère de l’Economie, des finances et de l’Industrie o Ville de Paris

5. Support Base o Area Attractiveness: unique context o - world leaders in the pharmaceutical industry in that area of the area/region o - 50% of French biotechnology companies 6. Cooperation and aggregation o - N.d. 7. Additional information o - N.d. 8. Sources o http://www.investinfrance.org/international/en/medicen-cluster.html

Plastipolis FRANCE

1. General Information o Cluster development stage o - Early stage and growing at accelerated pace: Established in 2005. - Rapid increase in the number of its members. They have risen from 80 in 2005 to 210 in 2008 o - Currently Plastipolis is the only competitive cluster for plastics engineering in France. o Cluster typology o - Brings together all the operators in the sector (companies, R&D centres, training centres and institutional investors) o Cluster objectives o - Facilitates the availability of innovation to small and medium-sized businesses and to provide greater added value to plastics engineering. 2. Scientific Base o Number of research institutes: o - Scientific Committee is made up of 22 members. These include 12 names of major ones, research focus manufacturers, 8 R&D and training centres and 2 associate members. areas and number of employees 3. Industrial Base o Number of large enterprises in o - By February 2009, Plastipolis included 150 companies, of which 90% small biotech: names of major ones, and medium-sized businesses, total turnover: 5,506 million Euros, Total number of employees: 29,990 employees, 37 R&D and training centres and 22 product focus areas, number of institutional investors. employees 4. Financial Base o - N.d. 5. Support Base o - N.d. 6. Cooperation and aggregation

10 Plastipolis FRANCE

o Cooperation other clusters in o - Seeks to improve the sector’s image nationally and internationally. different regions and/or countries 7. Additional information o - N.d. 8. Sources o http://www.plastipolis.fr/

Biotech (Munich Region) GERMANY

1. General Information o Cluster development stage o - Growing: Exceptional rate development in past few years. One of the leading biotechnology centers in Europe. o Cluster objectives o - Covers the entire range of biotechnological innovations and applications, including agro-biotechnology, bioanalytics and biodiagnostics, biomedical and pharmaceutical applications, industrial production of pharmaceuticals, additives for the food industry, renewable primary products and industrial bioproducts o - Bio-M activities for the Biotech Cluster consist of consulting and information services, networking activities, PR and marketing work 2. Scientific Base o Number of universities: names of o - University of Stuttgart, University of Tübingen, University of Hohenheim, major ones, research focus and the following universities of applied science: Albstadt-Sigmaringen, Esslingen, number of students Nürtingen, Reutlingen and Rottenburg. o Famous Scientists working on o - 17 of 19 of the noble prize winners for life science are from the region, have campus: e.g. Nobel Prize winners studied there or have worked there; example: Christiane Nüsslein-Volhard, director of Max-Planck institute in Tübingen. 3. Industrial Base o Number of large enterprises in o - Nearly 200 life science companies are working to improve health, the biotech: names of major ones, environment and agriculture. product focus areas, number of employees o Existing success stories in biotech: o - In May 2009, the Users’ Centre for Regenerative Medicine in the Neckar-Alb well-known products/ business and Stuttgart health region (REGiNA) was honoured as one of two winning cases/ companies projects in the “Gesundheitsregionen der Zukunft” (“Health Regions of the Future”) competition organised by the German Federal Ministry of Education and Research (BMBF). 4. Financial Base o - N.d. 5. Support Base o Area Attractiveness: unique context o - Muich alone is home to over 180 Life Science companies. of the area/region 6. Cooperation and aggregation o Cooperation other clusters in o - 2006: BioM Biotech Cluster Development GmbH was founded and takes different regions and/or countries over the marketing of the BioTech-Region Munich and the management within

11 Biotech (Munich Region) GERMANY

the Cluster Offensive Bavaria.

7. Additional information o - N.d. 8. Sources o http://www.bioregio-stern.de/en/background_and_objectives

Freiburg (Freiburg Region) GERMANY

1. General Information o - N.d. 2. Scientific Base o - N.d. 3. Industrial Base o - N.d. 4. Financial Base o - N.d. 5. Support Base o Area Attractiveness: unique context o - Ideal location for new and established companies engaged in biotechnology, of the area/region microsystems technology, medicine technology, pharmacy and related fields. o - Attractive and dynamic region, offering a high quality of life and an excellent and varied company and research landscape. 6. Cooperation and aggregation o Cooperation other clusters in o - partner tri-national BioValley network, which bundles the biotechnological different regions and/or countries potential of the centres Freiburg (D), Basel (CH) and Strasbourg (F), creating a world famous biotechnological site

7. Additional information o - N.d. 8. Sources o http://www.bioregio-stern.de/en/background_and_objectives

Heidelberg GERMANY

1. General Information o Cluster development stage o Place of research in diverse areas of both fundamental science and bioinformatics. o Had 31 DBFs in 1996; included already 82 DBFs in 2005. o Estimated ratio biomedical versus o Majority of companies are platform biotechs, hence low-risk and low-growth non-biomedical companies: XY profile in he long-term; some specialise in veterinary and environmental research. 2. Scientific Base o Number of universities: names of o the University of Heidelberg. major ones, research focus and

12 Heidelberg GERMANY

number of students o Number of research institutes: o the European Laboratory for Molecular Biology (EMBL), the German Cancer names of major ones, research focus Research Centre, the Max-Plank-Institutes for Medical Research and for Cell areas and number of employees Biology dissemination of entrepreneurial culture amongst researchers. 3. Industrial Base o Number of large enterprises in o Presence of the Big Pharma (e.g. BASF, Merck, Abbot, Roche Diagnostics) biotech: names of major ones, played a minor role in formation of DBFs: majority of spin-off and start-up product focus areas, number of initiated in the academic setting. employees o Existing success stories in biotech: o Initial single base factor was the excellence in research well-known products/ business o Growth started after winning German federal BioRegio competition in 1996 cases/ companies 4. Financial Base o Pre-seed capital funds: names of o private investments at the seed phase were encouraged through direct public funds, volume of capital under funding in the BioRegio competition. management, etc. 5. Support Base o Cluster promotion agencies (incl. o availability of support services, e.g. the Heidelberg Technology Park. Science parks, incubators): name, function o Public acceptance of biotech o Strong governmental intervention played a crucial role: activities: governmental support, o the Heidelberg Technology Park was established by the city of etc. Heidelberg and the Chamber of Industry and Commerce of Rhine- Neckar (1985) to provide hosting, but later expended its activities. o BioRegio competition of the German federal government (1995). o Securing equal amount of private funding in order to receive public funding. o Stimulated entrepreneurship. o Legal regime: specialized legal o Clear legal base: updates to German legislation provided clarity in terms of structures incl. tax cuts both. o Conducting research and the IP rights, such as. the Genetic Engineering Act. 6. Cooperation and aggregation o Cooperation other clusters in o geographical Rhine-Neckar area (ca 40 km radius) between thecities of different regions and/or countries Neustadt, Mannheim, Ludwigshafen, Darmstadt and Keiserlautern 7. Additional information o - N.d. 8. Sources

GERMANY Bio Region STERN (South West Germany)

1. General Information o Cluster development stage o Growing: STERN was founded in 2001.

13 GERMANY Bio Region STERN (South West Germany)

2. Scientific Base o Number of universities: names of o - Esslingen University of Applied Sciences offers courses in biotechnology and major ones, research focus and life sciences and the Käthe-Kollwitz Biotechnology High School has been run- number of students ning since 2002. 3. Industrial Base o Number of large enterprises in o - almost 100 medical techno-logy companies in the high-tech medtech biotech: names of major ones, environment of the STERN region. product focus areas, number of employees o Existing success stories in biotech: o - Won the BioProfile competition organised by the German Federal Ministry of well-known products/ business Education and Research (BMBF) in 2001. cases/ companies 4. Financial Base o Pre-seed capital funds: names of o - Investment funds are provided by public and private backers, companies and funds, volume of capital under other businesses. management, etc. 5. Support Base o Area Attractiveness: unique context o - The STERN BioRegion has a sophisticated structure of companies and of the area/region research institutes with outstanding biofuel expertise 6. Cooperation and aggregation o Cooperation other clusters in o - BioRegio STERN Management GmbH was founded in 2001 to develop the different regions and/or countries full economic scope of biotechnology in the region. o - STERN stands for Stuttgart, Tübingen, Esslingen, Reutlingen and Neckar- Alb - five dynamic biotech sites in South West Germany o - Strategy of “Thinking business forward”. Forum to discuss various issues and forge new partnerships.

7. Additional information o - N.d. 8. Sources o http://www.bioregio-stern.de/en/background_and_objectives

Oslo Teknopol NORWAY

1. General Information o Cluster objectives o - To provide free assistance and information to local and foreign investors considering the Oslo region as a possible location for future activities o - Main activities are Maritime, Energy and environmental technology, Life Science, Information and communication technology and Culture. o - Stimulate innovation and promote Norway's capital region in order to attract foreign investments and talent 2. Scientific Base o - N.d. 3. Industrial Base o - N.d.

14 Oslo Teknopol NORWAY

4. Financial Base o - N.d. 5. Support Base o Public acceptance of biotech o - Non-profit regional development agency, established by the City of Oslo and activities: governmental support, Akershus County Council. etc. 6. Cooperation and aggregation o - N.d. 7. Additional information o - N.d. 8. Sources o http://www.oslo.teknopol.no/English/

Bio Dundee SCOTLAND

1. General Information o Cluster development stage o Established in 1998. o Cluster typology o - Partnership between the public, private and academic sectors. o Cluster objectives o - BioDundee provide a wide range of business and research opportunities, from licensing and investment, through to joint ventures and collaborations. o - Mission is to build the strength of the life sciences sector in Dundee and Tayside internally and externally promote and position the Dundee life sciences sector as a centre of world class life science activity 2. Scientific Base o - N.d. 3. Industrial Base o - N.d. 4. Financial Base o - N.d. 5. Support Base o Area Attractiveness: unique context o - Over 4,000 people now work in Dundee's life sciences sector which accounts of the area/region for 16% of the local economy and is forecast to grow at 10% per annum over the next 3 years. 6. Cooperation and aggregation o - N.d. 7. Additional information o - N.d. 8. Sources o http://www.biodundee.co.uk/

Biotech Umeå SWEDEN

1. General Information o Cluster objectives o - Driving force helping the industry as well as the region to develop and reach a greater market. 2. Scientific Base o - N.d.

15 Biotech Umeå SWEDEN

3. Industrial Base o Existing success stories in biotech: o - Research centre Umeå Plant Science Centre was named as the best place to well-known products/ business work for postdocs outside of the USA by The Scientist. cases/ companies 4. Financial Base o - N.d. 5. Support Base o Public acceptance of biotech o - Umeå Bio frontrunner of Biotech Umeå. Cooperated and established Biotech activities: governmental support, Umeå with the Umeå university, the County Council of Västerbotten, the etc. County Administrative Board of Västerbotten and the association of biotech companies o Legal regime: specialized legal structures incl. tax cuts o Area Attractiveness: unique context o - More than 50 biotech companies in Umeå of the area/region - Advanced research in biotech is carried out at about ten institutions at the technological, natural sciences and medical faculties respectively 6. Cooperation and aggregation o - N.d. 7. Additional information o BioTech Umeå can draw on national and international experiences in order to market the region 8. Sources o http://www.biotechumea.se/default.asp?id=4069&PTID=&refid=4011

Uppsala BIO SWEDEN

1. General Information o - N.d. 2. Scientific Base o Number of universities: names of o - Academic research is mainly conducted within the two universities: the major ones, research focus and Swedish University of Agricultural Sciences and Uppsala University. number of students 3. Industrial Base o Number of large enterprises in o - Some of the affiliates include Pfizer, Neo-Pharma, Biotage, Crystal biotech: names of major ones, product focus areas, number of employees 4. Financial Base o - N.d. 5. Support Base o Cluster promotion agencies (incl. o - N.d. Science parks, incubators): name, function o Public acceptance of biotech o - Initiative from the local biotech industry, the two universities in Uppsala and activities: governmental support, regional development bodies etc. o Area Attractiveness: unique context o - Uppsala and Stockholm is home to more than 50 % of Sweden’s biotech

16 Uppsala BIO SWEDEN

of the area/region sector in the shape of universities, industry and national agencies. The region has the fourth largest biotech industry in Europe. o - Uppsala has a long tradition of working with biotechnology, especially tools and methods for research and development in the life sciences and diagnostics. o - Currently the Uppsala’s biotechnology sector employs some 8 000 people in over 100 companies. o - Biotech industry in Uppsala is particularly strong in three segments, namely tools and supplies, diagnostics and pharmaceuticals. 6. Cooperation and aggregation o - N.d. 7. Additional information o - N.d. 8. Sources o http://www.uppsalabio.com/DynPage.aspx?id=4706&mn1=1224

Nordwestschweiz (Basel), SWITZERLAND Part of Biovalley

1. General Information o Cluster objectives o - Aims to promote the Basel region as a prime location for Life Science companies, supporting life science entrepreneurs who wish to set up their company, enhancing communication with stakeholders and to foster contact among BioValley members from all countries and enhancing mutual support among them. 2. Scientific Base o - N.d. 3. Industrial Base o - N.d. 4. Financial Base o - N.d. 5. Support Base o Public acceptance of biotech o Non-Profit organization. activities: governmental support, etc. o Area Attractiveness: unique context o - Basel is a major center for pharmaceuticals, chemical, and modern of the area/region biotechnology industries. o - Over 900 life sciences companies are present in the BioValley region, which constitute about 40% of the world’s life sciences industry. o - employment growth of about 1,000 to 2,000 new jobs in the industry each year. o - Life sciences companies in the Basel area achieve an annual global turnover of over 100 billion dollars and an annual profit of close to 20 billion dollars. 6. Cooperation and aggregation o Cooperation other clusters in o - Biovalley is a cooperation between the Basel, Strasbourg and Freibourg different regions and/or countries clusters 7. Additional information o - N.d. 8. Sources o http://www.biovalley.ch/content.cfm?nav=3&content=16

17 Cambridge Cluster UK

1. General Information o Cluster development stage o - Environment provided by the strong scientific base of the University being an internationally recognized centre of excellence sine 1980s o - In 1980s was the first large European biotech cluster: a result of uncoordinated actions of different players - small and large companies, and the University. o - Exhibited rapid growth in 1995-1999 as a result of growing general awareness of the potential profitability of biotech. o - Access to large amount of funds (e.g. small private funds, venture capital) due to global economic growth. o - Growth slowed down from 2001/2 as a consequence of a plunge in global economy; as a result – fewer IPOs performed since then o - Currently the cluster is in a mature state. o Cluster typology o - No directed public intervention played a role in the appearance of the cluster; necessary environment (context factors) were present from the beginning. o - Interest in profit generating activities was present within the cluster already at the very beginning. o Number of publicly traded o - >160 DBFs (2005). companies o - Large number of small innovative companies present. 2. Scientific Base o Number of universities: names of o - University only recently started to directly coordinate establishment of major ones, research focus and academic spin-offs. number of students 3. Industrial Base o Number of large enterprises in o - Industrial actors (the Big Pharma and some large biotech companies) were biotech: names of major ones, important for promoting growth, but their role was indirect. product focus areas, number of employees o Number of biotech firms: names of o - Many large biotech companies that previously existed independently within major ones, product focus areas, the cluster have been acquired by larger companies or the Big Pharma, e.g. number of employees Celltech (became part of the UCB Group in 2004, and MedImmune (formerly Cambridge Antibody Technology, became first MedImmune, and then part of AstraZeneca in 2007.

4. Financial Base o Business Angels/Venture Capital o - Capital was made accessible through business angels’ activities (smaller seed Funds: names of funds, volume of phase investments) and venture capital funds. capital under management 5. Support Base o Cluster promotion agencies (incl. o - Presence of a science park: Trinity College (Cambridge University) rented Science parks, incubators): name, out premises to the start-ups. function o - Promotion agencies: BIA, EEDA. o Area Attractiveness: unique context o Availability of the hi-tech environment of electronics and computer companies of the area/region in 1980s 6. Cooperation and aggregation o - N.d. 7. Additional information o - N.d. 8. Sources o www.celltech.co.uk

18 Cambridge Cluster UK

o www.cambridgeantibody.com o www.bioindustry.org o www.eeda.org.uk

Oxford Cluster UK

1. General Information o Cluster development stage o The second most important cluster in the UK. o Appearance and spread of the entrepreneurial spirit among scientists was important in the formation of the cluster. o Cluster typology o Spontaneously appeared due to the context in the area. 2. Scientific Base o Number of universities: names of o Universities of Oxford and Oxford Brookes. major ones, research focus and number of students o Number of research institutes: o Oxford Radcliffe Hospitals, Central Laboratory of the Research Council, names of major ones, research focus CLRC Medical Research Council, MRC Radiobiology. areas and number of employees o Institute Radiation Oncology and Biology Centre and the Wellcome Trust Centre of Human Genetics . 3. Industrial Base o Number of large enterprises in o First biotech companies emerged in 1980s. biotech: names of major ones, o 85 companies (2005): 60 founded 1990-2005. product focus areas, number of o In 2005, majority of companies conducted drug development (34%) and employees diagnostics (17%). o Additionally, large number of service biotechs. o Presence of the Big Pharma, i.e. GlaxoSmithKlein, Eli Lilly, Merck, Novartis, Abbot, Pfizer. 4. Financial Base o Business Angels/Venture Capital o both university funding, and the presence of angel networks and VCs in the Funds: names of funds, volume of area. capital under management 5. Support Base o Cluster promotion agencies (incl. o technology transfer infrastructure, e.g. ISIS Innovation. Science parks, incubators): name, function 6. Cooperation and aggregation o Cooperation other clusters in o Oxfordshire Bioscience Network is now a member of the Biotechnology different regions and/or countries Industry Association: the world's largest biotechnology organisation, providing advocacy, business development and communications services 7. Additional information o - N.d. 8. Sources o www.bio.org

19 Oxford Cluster UK

o www.ox.ac.uk o www.brookes.ac.uk o www.oxfordradcliffe.nhs.uk o www.scitech.ac.uk o www.mrc.ac.uk o www.rob.ox.ac.uk o www.well.ox.ac.uk o www.obn.org.uk o www.isis-innovation.com

Clusters in North America

Saint-Hyacinthe Technopole CANADA

1. General Information o Cluster development stage o -Growing/Maturing. Founded in 1993.: Pioneer in agri-food, veterinary and agroenvironment biotechnology innovations. Solid foundations in research, teaching, services, etc. 2. Scientific Base o Number of universities: names of o - 5 educational institutions at the college, university, professional and major ones, research focus and continuing education levels. College and university-level institutions includes number of students the Faculty of Veterinary Medicine of the Université de Montréal, the ITA and the Cégep de Saint-Hyacinthe 3. Industrial Base o - N.d. 4. Financial Base o - N.d. 5. Support Base o - N.d. 6. Cooperation and aggregation o - N.d. 7. Additional information o - Host of the 1st International Conference of Science Parks specializing in agri- food and biotechnology in 1996 and the 2ind International Meeting of Agri- Food Science Parks in 1998. 8. Sources o http://www.sthyacinthetechnopole.qc.ca/client/pagesoussection.asp?cle f2=4#top_scroll

20 Massachusetts Life Sciences Center USA (Boston)

1. General Information o Cluster development stage o - Mature: Worldwide recognition in the life Sciences. o Cluster typology o - Hybrid: The MLSC was established to promote the life sciences within the Commonwealth of Massachusetts o - Dependant from private and federal investments. o Cluster objectives o - Strong focus on helping researchers and startup companies to succeed. o - expand the life sciences Supercluster including biotechnology, pharmaceuticals, medical devices, diagnostics and bioinformatics. o -Cluster invests public funds in strategic opportunities that create jobs, leverage private investment and expand scientific knowledge. 2. Scientific Base o - N.d. 3. Industrial Base o Number of large enterprises in o - Johnson &Johnson agreed to be the charter member of our Corporate biotech: names of major ones, Consortium Program. product focus areas, number of employees 4. Financial Base o - N.d. 5. Support Base o Public acceptance of biotech o - In 2008, Governor Deval Patrick announced the Massachusetts Life Sciences activities: governmental support, Act. The Initiative includes a $1 billion investment package (over ten years). etc. o - Quasi-public agency of the Commonwealth of Massachusetts, created by the Massachusetts legislature in June 2006

6. Cooperation and aggregation o - N.d. 7. Additional information o - The future of Massachusetts’ life-sciences cluster hinges on the ability of state and federal officials to complete billions of dollars in projects 8. Sources o http://www.mbl.edu/news/press_releases/pdf/mlsc_brochure_final.pdf o http://www.masslifesciences.com/mission.html

21 San Diego Cluster USA

1. General Information o Cluster development stage o - Mature: San Diego and the San Francisco Bay Area are home to two of the world's biggest biotech clusters. 2. Scientific Base o - N.d. 3. Industrial Base o - N.d. 4. Financial Base o - N.d. 5. Support Base o - N.d. o Area Attractiveness: unique context o - Biotechnology companies and the businesses that support them in San Diego of the area/region are responsible for 55,600 jobs and $5.8 billion in income. o - Cluster is most dense in terms of companies located within a compact geographic area o - Particular strength in research and development. o - Significant growth in biotech production process, thus creating a diverse set of biotech-related industries. o - life science industry in San Diego MSA is responsible for $5.8 billion, or 5.3 percent of gross metro product in the region 6. Cooperation and aggregation o - N.d. 7. Additional information o - Despite its strength in overall R&D, San Diego should acquire a greater share of funding distributed to research universities. 8. Sources o http://www.signonsandiego.com/news/business/biotech/20040608-9999- 1b8cluster.html o http://www.milkeninstitute.org/pdf/biotech_clusters.pdf?bcsi_scan_A8AC74D CFE366902=0&bcsi_scan_filename=biotech_clusters.pdf

22 Texas Bio Cluster USA

1. General Information o Cluster development stage o - Well positioned for exceptionally strong economic expansion o - Represents fast growing industries. o - Some areas of Texas have emerging clusters, such as the Dallas-Fort Worth Metroplex, which has a large aerospace and defense presence, and Houston which has an emerging biotechnology and life sciences concentration. 2. Scientific Base o Number of universities: names of o Baylor College of Medicine ranked,The University of Texas M.D., Anderson major ones, research focus and Cancer Center, The University of Texas, Southwestern Medical Center of number of students Dallas, The University of Texas Health Science Center at Houston , The Texas A&M University System, The University of Texas Medical Branch, The University of Texas Health Science Center at San Antonio 3. Industrial Base o - N.d. 4. Financial Base o Business Angels/Venture Capital o - Between 2000 and 2004, $360.8 million of private sector funded research and Funds: names of funds, volume of development has occurred in Texas. capital under management o - Total venture capital investment in Texas has yet to bounce back significantly – it dropped from a high of $6.2 billion in 2000 to $1.2 billion in 2003 o Government Funds: names of funds, o - Texas has doubled its funding from the National Science Foundation over the investment conditions, volume of past ten years. Since 1993, Texas has received $6.4 billion for research and capital development within the life science and biotechnology fields, 10.2% of which was used for infrastructure. 5. Support Base o Public acceptance of biotech o - Coordinates activities within the state to efficiently react to opportunities and activities: governmental support, threats affecting the cluster. etc. o Legal regime: specialized legal o - Gov. Rick Perry today announced a long-term, strategic job creation plan that structures incl. tax cuts will focus state efforts in six industry clusters. o Area Attractiveness: unique context o - Texas boast of the world’s largest medical center and it is the world’s capital of the area/region of human space flight, Texas also is home to outstanding technology, agricultural colleges and medical schools, engineers and scientists. o - Over the past five years, the biotechnology industry in Texas has experienced growth of 149% compared to the previous five years. 6. Cooperation and aggregation o - N.d. 7. Additional information o - N.d. 8. Sources o http://www.texasindustryprofiles.com/PDF/twcClusterReports/TexasBiotechno logyandLifeSciencesCluster.pdf?bcsi_scan_A8AC74DCFE366902=0&bcsi_sc an_filename=TexasBiotechnologyandLifeSciencesCluster.pdf o http://governor.state.tx.us/news/press-release/4530/ o http://www.texaswideopenforbusiness.com/assets/documents/biotech/Texas_B iotech_Industry_Report.pdf?bcsi_scan_A8AC74DCFE366902=j3xS5Upzl0lQ x0bfJh3gwQYAAACfUzUE&bcsi_scan_filename=Texas_Biotech_Industry_R eport.pdf o http://www.txbizbio.org/agenda.php

23 Clusters in Asia

Hong Kong Science and Technology Parks CHINA

1. General Information o Cluster development stage o Early development/Growing: opening of Phase 2 which doubles its size. Another expansion is currently being developed. Home to over 210 technology partner companies with 78 incubatees and companies in the Small Technology Enterprise Programme. o Cluster typology o - Companies ranging from start-up, SME to multi-national conglomerate both from local and overseas o 2. Scientific Base o Number of universities: names of o - Some of the universities include City University of Hong Kong, The Hong major ones, research focus and Kong University of Science and Technology, The University of Hong Kong number of students and Coventry University. o Other information o - Beginning April 2003, companies from the Incubation Programme have filed some 150 patents, trademarks and registered designs.

3. Industrial Base o Number of large enterprises in o - Home to more than 200 technology companies engaging in integrated circuits biotech: names of major ones, and electronics; precision engineering, biotechnology, green technology and product focus areas, number of ICT industries employees o - Alliances with some of the world’s leading companies including IBM,SMIC, Dongbu, Silterra, Chartered, TSMC, Fujitsu and e-Shuttle

4. Financial Base o Business Angels/Venture Capital o - Received more than 100 awards and raised nearly half a billion Dollars in Funds: names of funds, volume of venture capital. capital under management o Government Funds: names of funds, o - 2008: Government agreed loan facility HK$1,043,000,000 to the investment conditions, volume of Corporation repayable according to the repayment schedule issued by the capital o Government and bears interest at Government’s “no-gain-no loss” interest rate. - At 31 March 2008, loan from the Government outstanding amounted to HK$91,979,984.

5. Support Base o Cluster promotion agencies (incl. o - HKSTP only incubator in Asia among just 9 accredited SLIIs worldwide. Science parks, incubators): name, Overseas start-ups over the year were from Australia, Finland, Japan, Mainland function China, the Netherlands, Sweden and the United States.

o Public acceptance of biotech o -Non-profit statutory body set up by the Hong Kong Government Special activities: governmental support, Administrative Region etc. o - Previous years: Government granted both land and buildings of the Science Park Phase 1 development to the Corporation in December 2000 at a premium of HK$1,000 o - Government granted land of the Science Park Phase 2 development to the Corporation in 2003 at a premium of HK$1,000.

24 Hong Kong Science and Technology Parks CHINA

o Legal regime: specialized legal o - No provision for Hong Kong Profits Tax has been made in the financial structures incl. tax cuts statements as the Corporation is exempt from Hong Kong taxation in accordance with Section 25 of the Ordinance. o Area Attractiveness: unique context o - Hong Kong has unique, natural advantages as a hub fostering innovation and of the area/region technology, research and development 6. Cooperation and aggregation o Cooperation other clusters in o - In 2004 the Hong Kong Science and Technology Parks Corporation (HKSTP) different regions and/or countries formed a strategic alliance with ASAT Holdings Limited. - Strategic alliance between HKSTP and IBM in July 2007. o - Mainland China partnership: Networking with the Mainland China’s integrated circuits industry extended through partnerships with major IC design centres in Beijing, Shanghai and Chengdu.

7. Additional information o - The 22 hectare Hong Kong Science Park provides 20 state-of-the-art laboratory-fitted buildings offering 220,000 square meter office space. 8. Sources o http://www.hkstp.org/HKSTPC/en_html/en_about1_1.jsp http://www.hkstp.org/HKSTPC/download/annualReport/e_1012008112104253 8.pdf?bcsi_scan_A8AC74DCFE366902=0&bcsi_scan_filename=e_10120081 121042538.pdf

25 Shanghai Zhangjiang Hi-Tech Park CHINA

1. General Information o Cluster development stage o - Growing o Cluster typology o - Policy-driven o Cluster objectives o - Established a framework for biomedicine industry and information industry chain and innovation chain o Estimated ratio biomedical versus o - About half the Park revenues are from life sciences. non-biomedical companies: XY 2. Scientific Base o Other information o - Applied for 4,032 items of patent (833 of them granted) 3. Industrial Base o Number of large enterprises in o - More than 200 renowned domestic and overseas enterprises are located at biotech: names of major ones, Zhangjiang. product focus areas, number of o - 4297 new enterprises by 2005. employees o - 91 R&D centers of transnational enterprises. o - Mainly life science. 4. Financial Base o -N.d. 5. Support Base o -N.d. 6. Cooperation and aggregation o -N.d. 7. Additional information o - Attracted foreign investment of $13.748bn and a fixed asset investment 69.514bn RMB 8. Sources o http://www.zjpark.com/zjpark_en/zjgkjyq.aspx?id=7

26 China-Singapore Suzhou Industrial Park Venture Co., Ltd. (CSVC) CHINA

1. General Information o - N.d. 2. Scientific Base o - N.d. 3. Industrial Base o - N.d. 4. Financial Base o Business Angels/Venture Capital o -CSVC will also establish a biopharma incubator in the SIP BioBay for the Funds: names of funds, volume of invested enterprises through an angel fund. Tenant enterprises can receive capital under management support from CSVC such as free rental treatment, amongst other comprehensive services. 5. Support Base o - N.d. 6. Cooperation and aggregation o - N.d. 7. Additional information o - 50% – Research and Development; 30% – Commercial & Residential Facilities and 20% – Production. o - Aggressive, and focuses on early-stage and innovative companies. o - Young, energetic, and well-versed in English and Western-style business operations. o - The parks are known for consistent policies, pro-business mentalities, and large private funding networks. 8. Sources o http://www.genengnews.com/articles/chitem_print.aspx?aid=2883 o http://www.biobay.com.cn/en/aboutus.html

27 Zhong-guan-cun (ZGC) Life Science Park CHINA

1. General Information o Cluster development stage o - Mature: One of China’s older biotech parks o Cluster typology o - Policy-driven: Developed according to the Written Approval from the State Council, to launch the Beijing "248" Technology Innovation Project, and to develop the knowledge-based economy in the capital area. o Cluster objectives o - Responsible for the work of primary land development and business promotion. Aiming to build a national innovation base for life sciences, new medicines, and advanced pharmaceuticals 2. Scientific Base o Number of universities: names of o - The Institute of Biotechnology, Beijing Normal University, Peking major ones, research focus and University, Beijing University, and other universities are located here. number of students 3. Industrial Base o Number of large enterprises in o - Genzyme and Bayer Schering both have announced plans to develop R&D biotech: names of major ones, centers there. product focus areas, number of employees 4. Financial Base o - N.d. 5. Support Base o Cluster promotion agencies (incl. o - Five technology support systems are set up in the park in accordance with the Science parks, incubators): name, planning. The incubator is not only oriented to serve for the whole park, but function also to undertake the risk operation of incubating small and medium R&D projects and career-developing enterprises. Thus the incubator is a necessary infrastructure of Zhong-guan-cun Life Science Park. o Public acceptance of biotech o - Professional science park developed by the Beijing Municipal Government. activities: governmental support, o - Closely tied with major national developmental projects in the life sciences etc. field 6. Cooperation and aggregation o - N.d. 7. Additional information o - Important part of ZGC Science and Technology Park system. o - Park will be developed into an international high-tech park, integrating R&D of life sciences, enterprise nurturing, mid-test and production, result appraisal, bio-technology project issuance, venture capital, international exchange and personnel training. o - Still a lot of concerns about intellectual property in China. o - Companies and universities are doing discovery research, and clinical trials, but the industry hasn’t yet moved into late-stage research. 8. Sources o http://www.lifesciencepark.com.cn/en/ryqy/index.asp

28 Genome Valley Cluster, Hyderabad INDIA

1. General Information o Cluster development stage o - Over 100 biotech companies o Cluster typology o - Policy-driven o - State government was developing the third phase of Genome. 2. Scientific Base o Number of universities: names of o - University of Hyderabad major ones, research focus and number of students o Number of research institutes: o - Life Sciences R&D institutions: CCMB, IICT, CDFD, NIN, ICRISAT. names of major ones, research focus areas and number of employees 3. Industrial Base o Number of large enterprises in o - Biopharma Companies include: Shantha Biotechnics, Indian Immunologicals, biotech: names of major ones, Bharat Biotech, Biological Evans, Krebs Biochedmicals, Ocimum product focus areas, number of Biosolutions, Dr. Reddy’s Laboratories etc. employees 4. Financial Base 5. Support Base o Cluster promotion agencies (incl. o - Agri-business Incubator present. Science parks, incubators): name, - Biotech incubation centre would be set up and be supported with technical function inputs from the Indian Institute of Chemical Technology, Hyderabad. o Public acceptance of biotech o - Joint initiative of ICICI Bank and the Andhra Pradesh government. activities: governmental support, etc. o Area Attractiveness: unique context o - Genome Valley provides world-class infrastructure facilities to over 100 of the area/region biotech companies. 6. Cooperation and aggregation o – N.d. 7. Additional information o - IKP Knowledge Park (Former name ICICI) nestles in a 200-acre pollution free zone in Genome Valley, Hyderabad.

8. Sources o http://www.iciciknowledgepark.com/icicikp/index.asp o http://www.ticelbiopark.com/features.html

29 Ticel Bio Park (Chennai) INDIA

1. General Information o Cluster development stage o - Early Development: Established in 2004. o Cluster typology o - Hybrid: Both banks and the state of Tamilnadu played a significant role in the development. 2. Scientific Base o – N.d. 3. Industrial Base o – N.d. 4. Financial Base o Pre-seed capital funds: names of o - Support / financial assistance (Equity / Term loan) was provided by TIDCO, funds, volume of capital under TIDEL, Indian Bank, Karur Vysya Bank and Bharat Overseas Bank. management, etc. 5. Support Base o – N.d. 6. Cooperation and aggregation o – N.d. 7. Additional information o - Provides world class laboratory infrastructure and services for Biotech R&D o - Implemented 5 acres of land in Chennai at a capital outlay of Rs.625 million (US$ 12.5 million) has now achieved 100% occupancy with National and International clients. 8. Sources o http://www.iciciknowledgepark.com/icicikp/index.asp o http://www.ticelbiopark.com/features.html

30 Hokkaido BIO Industrial Cluster Forum JAPAN

1. General Information o Cluster development stage o - Growing o Cluster typology o - Spontaneous o - Mainly consists of venture companies. o - Hokkaido's bio-industry cluster is qrowing and developing uniquely, centering on university-launched ventures and small to medium sized businesses.

2. Scientific Base o - N.d. 3. Industrial Base o - N.d. 4. Financial Base o - N.d. 5. Support Base o - N.d. 6. Cooperation and aggregation o Cooperation other clusters in o - Hokkaido Bureau of Economy, Trade and Industry launched the “Hokkaido different regions and/or countries Super Cluster Promotion Project” in April 2001 o Cooperation or aggregation via other o - In 2007, the Hokkaido Bio-industry Development Strategy” was developed, means an effective cycling of products, aimed at facilitating exchanges between bioindustry and unique regional industries, such as agriculture, forestry, fisheries, and food industries. 7. Additional information o - Agriculture and food industry has the largest percentage, followed by medical care and pharmaceutical industry. Both industries account for about 70% of the cluster. - Faced with problems, such as a shortfall in human resources with managerial abilities and lack of marketing power.

31 NPO Bio Factory Central Japan JAPAN

1. General Information o Cluster objectives o - Target of "Tokai Bio Factory Project" is the formation of a bio-industrial cluster in this area and the increase of local industrial competitiveness. o Number of publicly traded o - 74 companies (including 5 financial institutions) companies 2. Scientific Base o Number of universities: names of o - 47 universities and public research institutes major ones, research focus and number of students 3. Industrial Base o – N.d. 4. Financial Base o – N.d. 5. Support Base o Public acceptance of biotech o - 4 local government organizations activities: governmental support, etc. 6. Cooperation and aggregation o – N.d. 7. Additional information o – N.d. 8. Sources o http://www.cluster.gr.jp/en/Action/chubu2.html

32 Songdo Techno Park SOUTH-KOREA

1. General Information o Cluster development stage o - Early development: o - First Biocluster in Korea as from April 2008. o Cluster typology o - Policy-driven: Established in 1998 as a non-profit organization. o Cluster objectives o - Aim is to increase the technological competitiveness of small- and medium- sized enterprises. 2. Scientific Base o – N.d. 3. Industrial Base o Number of large enterprises in o - 54 Korean companies, including CJ and LG Life Science, have said they will biotech: names of major ones, move to the complex, investing $1.1 billion as of October 2007. product focus areas, number of employees 4. Financial Base o Business Angels/Venture Capital o - VGX Pharmaceutical, a U.S. drug developer and manufacturer, has signed a Funds: names of funds, volume of deal to invest $200 million to establish its Asian regional headquarters in the capital under management complex. 5. Support Base o Public acceptance of biotech o - Non-profit foundation established together with the University of Incheon, activities: governmental support, Inha University, and Korea Institute of Industrial Technology etc. o Legal regime: specialized legal o - Foreign companies seeking to invest in the complex will be exempt from rent structures incl. tax cuts and corporate taxes for five to seven years, and the local government will offer additional tax benefits. 6. Cooperation and aggregation o – N.d. 7. Additional information o -Completion is scheduled for late 2010. 8. Sources o http://www.bio-hub.org/eng/networking/bioclusters.jsp o http://www.korea.net/News/news/newsView.asp?serial_no=20080402008&par t=107&SearchDay=&page=7

33 Biopolis Singapore SINGAPORE

1. General Information o Cluster development stage o - Launched in 2003: Early development. o - Asia's leading center for biomedical sciences research and development. o Cluster typology o - Launched by Singaporian government. 2. Scientific Base o – N.d. 3. Industrial Base o Number of large enterprises in o - Tenants of the complex include pharmaceutical companies such as biotech: names of major ones, GlaxoSmithKline and Novartis, as well as biotech firms like SingVax and product focus areas, number of CombinatoRx. employees 4. Financial Base o Government Funds: names of funds, o - Measures within the framework of the Upper Austrian Food Cluster are investment conditions, volume of financed by the Province of Upper Austria, the Upper Austrian Chamber of capital Commerce and contributions from network partners. 5. Support Base o Area Attractiveness: unique context o - Biopolis is home to more than 2,000 scientists. This research community is of the area/region fully supported by state-of-the-art infrastructure including shared resources and services catering to the full spectrum of R&D activities and graduate training 6. Cooperation and aggregation o Cooperation other clusters in o - Use of synergy to enhance innovatory strength improves regional and supra- different regions and/or countries regional competitiveness. - Increasing competitiveness and innovatory strength through co-operation is highly emphasized. o Cooperation or aggregation via other o - Close co-operation within the LC OÖ network between the farming industry means and commerce. Over 1.000 farmers are involved in LC OÖ projects. 7. Additional information o - Biopolis allows start-up companies to reduce their R&D costs by taking advantage of shared facilities and shared scientific equipment such as X-ray crystallography and MRI equipment